Medical Journals Publishing
Login


International Journal of Integrative and Modern Medicine

 Submit manuscript

Systemic Immune–Inflammatory Indices in Gout: Clinical and Prognostic Value With Emphasis on the Systemic Immune-Inflammatory Index (SII)

Vol. 3 No. 12 (2025): International Journal of Integrative and Modern Medicine:
Published : Dec 20, 2025

Oygul Ikramovna Khadzhimetova (1), Jamshid Ikromovich Reymberganov (2), Izzat Davranbekovich Khusinbayev (3)

(1) Assistant of the Department of Internal Medicine, Nephrology, Hemodialysis and Rehabilitation, Urgench Branch of the Tashkent Medical Academy, Uzbekistan
(2) Urgench State Medical Institute, Khorezm branch of the Republican Emergency Medical Center, Urgench, Uzbekistan, Uzbekistan
(3) Department of Internal Diseases, Nephrology, Hemodialysis, and Rehabilitology, Urgench State Medical Institute, Urgench, Uzbekistan, Uzbekistan
Fulltext View | Download

Abstract:

Gout is a chronic crystal-induced inflammatory disease characterized by recurrent flares and persistent hyperuricemia. Traditional inflammatory markers such as C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) are commonly used to assess disease activity, yet they often fail to reliably reflect subclinical inflammation or predict long-term outcomes. In recent years, systemic immune–inflammatory indices (SIIs)—including the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR), and particularly the systemic immune-inflammatory index (SII)—have emerged as promising biomarkers. This article provides a detailed analysis of the clinical and prognostic significance of these indices in gout, focusing on the SII as a comprehensive marker integrating neutrophil, platelet, and lymphocyte counts. The work summarizes pathophysiological mechanisms, diagnostic value, prognostic utility, correlation with comorbidities, and the potential role of SII in personalized treatment strategies.

References

1. Dalbeth N, Gosling AL, Gaffo A, Abhishek A. Gout. Lancet. 2021; 397(10287):1843–1855.

2. Richette P, Doherty M, Pascual E, et al. 2018 updated EULAR evidence-based recommendations for the diagnosis of gout. Ann Rheum Dis. 2020; 79(1):31–38.

3. So AK, Martinon F. Inflammation in gout: mechanisms and therapeutic targets. Nat Rev Rheumatol. 2017;13(11):639–647.

4. Martinon F, Pétrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NLRP3 inflammasome. Nature. 2006;440:237–241.

5. Desai J, Foresto-Neto O, Honarpisheh M, et al. Neutrophil extracellular traps promote NLRP3 inflammasome activation in gout. J Clin Invest. 2017;127(6):2262–2275.

6. Hu B, Yang XR, Xu Y, et al. Systemic immune-inflammation index predicts prognosis of patients with hepatocellular carcinoma. Oncotarget. 2014;5(17):7617–7629.

7. Fois AG, Paliogiannis P, Scano V, et al. The systemic inflammation index on admission predicts in-hospital mortality in COVID-19 patients. Molecules. 2020;25(23):5725.

8. Fest J, Ruiter R, Ikram MA, et al. Reference values for white blood-cell-based inflammatory markers. Sci Rep. 2018;8:10967.

9. Li S, Liu K, Gao Y, et al. Systemic immune-inflammation index as a biomarker in inflammatory and metabolic diseases. Front Immunol. 2022;13:889970.

10. Li Q, Wang Y, Ding X, et al. Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with gout. Clin Rheumatol. 2021;40:2765–2773.

11. Zhang Y, Luo Q, Zhang X, et al. Association of systemic immune-inflammatory index with hyperuricemia and gout. Rheumatol Int. 2023;43:1121–1130.

12. Huang J, Li H, Huang X, et al. Inflammatory indices and disease activity in gouty arthritis. Int J Rheum Dis. 2022;25(4):468–476.

13. Clarson LE, Chandratre P, Hider SL, et al. Increased cardiovascular mortality associated with gout. Ann Rheum Dis. 2015;74(4):642–647.

14. Li L, Yang C, Zhao Y, et al. Is hyperuricemia an independent risk factor for new-onset chronic kidney disease? Kidney Int. 2014;85(3):620–628.

15. Borghi C, Rodriguez-Artalejo F, De Backer G, et al. Serum uric acid and the risk of cardiovascular disease. Eur J Prev Cardiol. 2020;27(8):866–878.

16. Zhang M, Gao Y, Wang X, et al. Systemic immune-inflammatory index and metabolic syndrome. Diabetes Metab Syndr Obes. 2021;14:3955–3966.

17. Dalbeth N, Choi HK, Joosten LAB, et al. Gout. Nat Rev Dis Primers. 2019;5:69.

18. Howard RG, Pillinger MH, Gyftopoulos S, et al. Reproducibility of dual-energy CT in gout. Rheumatology. 2014;53(9):1622–1627.

19. Stamp LK, Dalbeth N. Urate-lowering therapy: current options and future prospects. Lancet Rheumatol. 2021;3(6):e381–e392.

20. Perez-Ruiz F, Desideri G. Improving outcomes in gout: treat-to-target approach. Rheumatology. 2018;57(suppl_1):i20–i26.